Alzheimer Disease
Conditions
Keywords
Dementia, Stem cells, Alzheimer's Disease
Brief summary
The purpose of this research study is to test the safety, possible side effects, and possible effectiveness of mesenchymal stem cell infusions when given to people with a diagnosis of mild to moderate Alzheimer's disease.
Interventions
BIOLOGICALApproximately 100 million cells allogeneic hMSC
Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of approximately 100 million cells per infusion.
Sponsors
Bernard (Barry) Baumel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
All subjects enrolled in this trial must: 1. Provide written informed consent 2. Male or female subjects aged 50-85 years at time of signing Informed Consent 3. Mini-Mental State Examination (MMSE) between 20-26 4. Amyloid PET scan or CSF Aß1-42 positive for the presence of amyloid 5. Meet criteria for either Alzheimer's Disease or probable Alzheimer's Disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINDCDS/ARDRA) 6. Subjects, if taking cholinesterase inhibitor medications (donepezil, rivastigmine (oral or transdermal) or galantamine), are required to have been taking them on a stable dose for at least 3 months prior to Baseline Visit These medicines are not required 7. Subjects already taking memantine will not have an effect in the inclusion/
Exclusion criteria
. 8. Have a study partner 9. No clinically significant abnormal screening laboratory values, as determined by the investigator 10. Women must be postmenopausal, surgically sterile, or having infertility. A postmenopausal woman is defined as either having an intact uterus with at least 12 months of spontaneous amenorrhea or a diagnosis of menopause, defined as an Follicular Stimulating Hormone (FSH) level of \> 25 IU/L
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs) | One month post-infusion | All adverse events will be evaluated by the investigator for relationship with the study intervention. Treatment-Emergent Serious Adverse Events is defined as any untoward medical occurrence with a reasonable possibility that it is caused by the study intervention that: * Is life-threatening (e.g.; leads to stroke or non-fatal pulmonary embolism); * Requires inpatient hospitalization or prolongation of existing hospitalization; * Results in persistent or significant disability/incapacity * Results in other clinically significant sign(s) or symptom(s), (e.g.; clinically asymptomatic brain microhemorrhages); or * Results in death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11) | Up to Week 65 | The ADAS-Cog 11 is a 13-item version of ADAS-Cog comprising of the original 11-item ADAS-Cog as well as Delayed Recall and Digit Cancellation items. The total score ranges from 0-85 points, with a lower score indicating better performance. |
| Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test | Up to Week 65 | The MMSE assesses orientation to time and place, immediate and delayed recall of words, attention and calculation, language (naming, comprehension and repetition), and spatial ability (copying a figure). The total score ranges from 0-30, with a higher score indicating better cognitive performance. |
| Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version | Up to Week 65 | The GDS is a 15-item questionnaire with each item counting as one point. The total score ranges from 0 to 15 with a score greater than 5 indicating possible depression. |
| Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver | Up to Week 65 | ADRQL-40 is a questionnaire completed by the caregiver assessing the quality of life of the participant with AD. The total score for the ADRQL is computed by summing the values assigned to the responses, dividing the sum by the maximum value for the scale and multiplying the results by 100 to obtain a percentage score of 0 to 100. A higher score reflects a higher quality of life. |
| Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver | Up to Week 65 | The ADCS-ADL is a 23 item questionnaire completed by the caregiver assessing the basic and instrumental activities of daily living by the AD participant. Total score range from 0-78 with the higher score indicating increased independence. |
| Neuropsychiatric Inventory-Q (NPI-Q) Scores over time | Up to Week 52 | The NPI-Q is a questionnaire used to assess behavioral changes common in dementia patients. This questionnaire is completed by the caregiver. The questionnaire consists of 12 items with each item having a scoring range between 0-3. The higher score indicates a more severe neuropsychiatric symptomatology. |
| Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores | Up to Week 52 | The Caregiver Self-Assessment questionnaire is completed by the caregiver. It is an 18-item questionnaire answered with a "yes" or "no". Evidence of distress is indicated for having over 10 "yes" answers. |
| Biomarker levels over time | Up to Week 65 | Serum blood inflammatory and biomarker levels will be evaluated including Interleukin-6 (IL-6), Neurofilament light (NfL), Amyloid Beta 40 (Aβ40) and Amyloid Beta 42 (Aβ42) in pg/mL. |
| Serum ApoE level over time | Up to Week 65 | Serum blood Apolipoprotein E (ApoE) will be evaluated in mg/dL. |
| Serum PRA level over time | Up to Week 65 | Serum blood Plasma Renin Activity (PRA) will be evaluated in ng/mL per hour. |
| Serum Tau protein level over time | Up to Week 65 | Serum blood Tau protein level will be evaluated in ng/L. |
| Cerebrospinal Fluid (CSF) Biomarker levels over time | Up to Week 52 | CSF inflammatory and biomarker levels will be evaluated including Interleukin-6 (IL-6), Neurofilament light (NfL), Amyloid Beta 40 (Aβ40) and Amyloid Beta 42 (Aβ42) in pg/mL. |
| CSF ApoE level over time | Up to Week 52 | CSF Apolipoprotein E (ApoE) levels will be evaluated in mg/dL. |
| CSF PRA level over time | Up to Week 52 | CSF Plasma Renin Activity (PRA) levels will be evaluated in ng/mL per hour. |
| CSF Tau protein level over time | Up to Week 52 | CSF Tau protein levels will be evaluated in ng/L. |
| Change in hippocampal volume | Baseline to Week 6, Baseline to Week 52 | Change in hippocampal volume will be assessed via MRI Brain volumetric studies |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORBernard (Barry) Baumel, MD
University of Miami
Outcome results
None listed